Astra goes pivotal with CTLA-4
Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.
Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.
After generating unexpectedly positive TIGIT data Roche moves to launch a phase 3 trial.